Vpr in plasma of HIV type 1-positive patients is correlated with the HIV Type 1 RNA Titers

AIDS Research and Human Retroviruses

Volumn 23, Issue 3, 2007, Pages 391-397

  Hoshino, Shigeki ^a,b   Sun, Binlian ^a   Konishi, Mitsuru ^c   Shimura, Mari ^a   Segawa, Tatsuya ^d   Hagiwara, Yoshiaki ^d   Koyanagi, Yoshio ^e   Iwamoto, Aikichi ^f   Mimaya, Jun Ichi ^g   Terunuma, Hiroshi ^h   Kano, Shigeyuki ^a,b   Ishizaka, Yukihito ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d Immuno Biological Laboratories Co Ltd   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^h Biotherapy Institute of Japan   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; VPR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS LOAD; VIRUS TITRATION;

ADULT; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CROSS-SECTIONAL STUDIES; FEMALE; GENE PRODUCTS, VPR; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, VIRAL; VIRAL LOAD;

EID: 34247243517     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0124     Document Type: Article

References (18)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
3. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS: Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238:800-802.
4. Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, and Chen ISY: Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988;241:1673-1675.
5. Heinzinger NK, Bukrinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, et al.: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994;91:7311-7315.
6. Vodicka MA, Koepp DM, Silver PA, and Emerman M: HIV-1 vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998;12:175-185.
7. Jenkins Y, McEntee M, Weis K, and Greene WC: Characterization of HIV-1 vpr nuclear import: Analysis of signals and pathways. J Cell Biol 1998;143:875-885.
8. Levy DN, Refaeli Y, MacGregor RR, and Weiner DB: Serum vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1994;91:10873-10877.
9. Levy DN, Refaeli Y, and Weiner DB: Extracellular vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 1995;69: 1243-1252.
10. Marzio PD, Choe S, Ebright M, Knoblauch R, and Landau NR: Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 vpr. J Virol 1995;69:7909-7916.
11. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, et al.: HIV-1 vpr induces apoptosis through caspase 9 in T cells and peripheral mononuclear blood cells. J Biol Chem 2002; 277:37820-37831.
12. Muthumani K, Hwang DS, Choo AY, Mayilvahanan S, Dayes NS, Thieu KP, et al.: HIV-1 vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 2004; 17:103-116.
13. Muthumani K, Choo AY, Zong W-X, Madesh M, Hwang DS, Premkumar A, et al.: The HIV-1 vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol 2006;8:170-179.
14. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao X-J, et al.: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 2003; 111:1547-1554.
15. Rodes B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, et al.: Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 2004;18:1109-1116.
16. Mologni D, Citterio P, Menzaghi B, Zanone PB, Riva C, Broggini V, et al.: Vpr and HIV-1 disease progression: R77Q mutation is associated with long term control of HIV-1 infection in different groups of patients. AIDS 2006;20:567-574.
17. Cavert W, Webb CH, Balfour HH Jr: Alterations in the C-terminal region of HIV-1 accessory gene vpr do not confer clinical advantage to subjects receiving nucleoside antiretroviral therapy. J Infect Dis 2004;20:2181-2184.
18. Chui C, Cheung PK, Brumme CJ, Mo T, Brumme ZL, Montaner JSG, et al.: HIV-1 VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. AIDS Res Hum Retrovir 2006;22:615-618.